-5%
Ivermectin acts by selectively binding with high affinity to glutamate-gated chloride ion channels found in invertebrate nerve and muscle cells. This binding increases membrane permeability to chloride ions, resulting in hyperpolarization of nerve and muscle cells, paralysis, and eventual death of the parasite.
Pediatric Use: Safety and efficacy have not been established in children weighing less than 15 kg.
Geriatric Use: Limited data are available to determine differences in response in patients aged 65 years and above.
Ivtin tablet is indicated for the treatment of the following parasitic infections:
- Strongyloidiasis
- Onchocerciasis
- Filariasis
- Scabies
- Head lice
Intestinal Strongyloidiasis:
Ivtin is indicated for the treatment of non-disseminated intestinal strongyloidiasis caused by Strongyloides stercoralis. Clinical studies, including comparative and open-label trials, have demonstrated cure rates ranging from 64% to 100% following a single oral dose of 200 mcg/kg.
Onchocerciasis:
Ivtin is used for the treatment of onchocerciasis caused by Onchocerca volvulus. This indication is supported by randomized, double-blind, placebo-controlled, and comparative studies conducted in endemic regions of West Africa, involving over 1,400 patients. Comparative trials used diethylcarbamazine citrate (DEC-C) as a reference treatment.